ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

About this update from Endra Life Sciences Inc.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), reported financial results for the quarter ended June 30, 2026, and provided a business update. Second Quarter 2026 and Recent Highlights On June 25, 2026, ENDRA entered into a definitive merger agreement with ASP Isotopes Inc. (NASDAQ: ASPI), Noble Africa LLC (“Noble Africa”) , Renergen Limited and other parties thereto. Under the terms of the agreement, Noble Africa will merge with a wholly owned subsidiary of ENDRA, with Noble Africa surviving the merger as a wholly owned subsidiary of ENDRA. Upon completion of the proposed transaction, ENDRA will be renamed Noble Africa Inc. The proposed transaction is intended to provide investors with exposure to Renergen’s Virginia Gas Project in South Africa. In connection with the transaction, Noble Africa entered into subscription agreements with institutional and other investors, as well as ASP Isotopes, for a private placement expected to generate approximately $50 million in gross proceeds, with closing anticipated concurrently with closing of the merger. Closing of the merger is expected in the fourth quarter of 2026, subject to customary closing conditions, including applicable stockholder and regulatory approvals. On May 28, 2026, ENDRA completed a $3.8 million private placement, strengthening the Company’s balance sheet and providing additional capital as it pursued its strategic alternatives process. As of June 30, 2026, the $3.8 million of proceeds were classified as restricted cash pursuant to the terms of the financing. Continued Disciplined Management of Operating Resources ENDRA continued to carefully manage operating expenditures and cash resources during the quarter while completing its strategic alternatives process and entering into the proposed Noble Africa transaction. Research and development expenses decreased 39% and sales and marketing expenses decreased 92% compared with the second quarter of 2025. “During the second quarter, we achieved an important objective for ENDRA and its stockholders by entering into a definitive merger agreement with Noble Africa following our strategic alternatives process,” said Alexander Tokman, Chairman and Chief Executive Officer of ENDRA Life Sciences. “We believe the proposed t...

View stock analysis, news, and events for Endra Life Sciences Inc.